Novartis (VTX:NOVN) received a CHF 78 price target from investment analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Friday, Borsen Zeitung reports. The brokerage currently has a “sell” rating on the stock.
Several other research analysts have also commented on the stock. UBS Group set a CHF 82 price objective on shares of Novartis and gave the stock a “neutral” rating in a report on Wednesday, April 24th. HSBC set a CHF 83 price objective on shares of Novartis and gave the stock a “neutral” rating in a report on Thursday, April 25th. Deutsche Bank set a CHF 85 price objective on shares of Novartis and gave the stock a “neutral” rating in a report on Friday, April 5th. Goldman Sachs Group set a CHF 110 price objective on shares of Novartis and gave the stock a “buy” rating in a report on Thursday, January 24th. Finally, Barclays set a CHF 75 price objective on shares of Novartis and gave the stock a “sell” rating in a report on Friday, February 1st. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of CHF 88.41.
Novartis has a 1-year low of CHF 72.45 and a 1-year high of CHF 88.30.
Novartis Company Profile
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Further Reading: How interest rates affect municipal bond prices
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.